- Home
- REGN vs PSA Comparison
REGN vs PSA Comparison
Compare REGN & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REGN | PSA |
|---|---|---|
| Founded | 1988 | 1972 |
| Country | United States | United States |
| Employees | 15410 | 5770 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8B | 54.4B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | PSA |
|---|---|---|
| Price | $656.01 | $322.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $830.16 | $310.08 |
| AVG Volume (30 Days) | 720.4K | ★ 1.0M |
| Earning Date | 04-29-2026 | 04-27-2026 |
| Dividend Yield | 0.55% | ★ 4.08% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $12.45 | $2.84 |
| Revenue Next Year | $10.13 | $5.55 |
| P/E Ratio | $96.58 | ★ $33.19 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $256.54 |
| 52 Week High | $821.11 | $331.79 |
Technical Indicators
Market Signals| Indicator | REGN | PSA |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 53.81 |
| Support Level | $648.66 | $291.99 |
| Resistance Level | $670.96 | $330.51 |
| Average True Range (ATR) | 15.37 | 6.55 |
| MACD | -0.65 | -0.92 |
| Stochastic Oscillator | 40.76 | 61.44 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About PSA Public Storage
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,500 self-storage facilities in 40 states and approximately 258 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.